Health
Moderna Raises Covid Shot Sales Guidance on Japan, US Pacts
- Vaccine sales forecast increased by at least $1 billion
- Company looks to late-stage pipeline for future revenue
This article is for subscribers only.
Moderna Inc. raised its Covid-19 vaccine sales outlook for the year, finalizing contracts with Japan and several American health-care companies as the US government largely stops paying for the shots.
Moderna now sees sales of $6 billion to $8 billion, according to a statement Thursday, up from a previous prediction of at least $5 billion and in line with the analysts’ average estimate of $6.9 billion. The company is in talks with purchasers in the US, European Union and other parts of the world for more potential orders, and $1 billion in previously anticipated 2023 sales were pushed to 2024.